An interventional study of Exercise and Exercise in Parkinson Disease, sponsored by Pacific Parkinson's Research Centre. Terminated at 1 site in Canada. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-17.
Sponsored by Pacific Parkinson's Research Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 253 studies in Parkinson Disease with a site in Canada — 43 open to participants now, 62 under way, 3 of them phase 3. Parkinson Disease · Canada.
Among the 253 studies in Parkinson Disease with a site in Canada, this one is the 155th largest by enrollment of the 212 interventional ones that give a count, is one of 12 that started in 2014, is one of 95 with no phase, and was the 85th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →43 of the 253 studies in Parkinson Disease with a site in Canada are open now. Recruiting first, the newest first:
Vima Therapeutics · Sites in Canada, United States
Ages 18–65
AbbVie · Sites in Canada, United States, Croatia and 6 more countries
Ages 18–69
Centre intégré de santé et de services sociaux de l'Outaouais · Sites in Canada
Ages 50+ · Healthy volunteers
Regeneron Pharmaceuticals · Sites in Canada, Netherlands
Ages 50–80
University Health Network, Toronto · Sites in Canada
Ages 18–85 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
253 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 47 · Phase 3 57 · Phase 4 4
First in 1998; this study’s year is marked. 12 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 60 across the 212 interventional studies, 315 across the 41 observational. Of the 158 that completed or were terminated, 60 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 253 have an industry lead sponsor. The 10 most frequent:
Pacific Parkinson's Research Centre is the lead sponsor of 7 studies on the registry; none are open to participants now.
Pacific Parkinson's Research Centre has 7 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Parkinson Disease with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06529744University Health Network, TorontoImproving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling | 2026-11 |
| NCT04426786Pacific Parkinson's Research CentreExercise & Brain Energetics in PD | 2026-12-30 |
| NCT07443293University of British ColumbiaIMPACT 360 for Parkinson's Disease | 2026-12-31 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT05897957BlueRock TherapeuticsContinued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01 | 2027-05 |
Add all 13 to your calendar (.ics) → With an account.
Among the 253 studies in Parkinson Disease with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The therapeutic effects of exercise in Parkinson's disease (PD) are commonly reported, however the mechanisms are unknown. The purpose of this study is to investigate the potential mechanisms of exercise in the brain for the treatment of PD.
Positron Emission Tomography will be used to measure dopamine neuron density, endogenous dopamine release and neuroimflammation. We will also use functional magnetic resonance imaging (fMRI) to measure brain activity. Assessments will be conducted before and after a 12-week exercise intervention and 3-year follow-up. Participants will be randomly allocated into either an aerobic or a stretching intervention. Clinical measures of motor function, cognition and mood will also be assessed.
Inclusion Criteria: Diagnosed with Parkinson's Disease, Exercise less than 3x per week.
Exclusion Criteria. Describe which potential participants will be excluded from participation, and list the criteria for their exclusion.
Exclusion criteria for MRI scanning and magnetic stimulation from repetitive Transcranial Magnetic Stimulation (rTMS) scanning includes:
Subjects may be excluded following study enrollment if they meet any of the following exclusion criteria:
One type of exercise
Other: Exercise
A different type of exercise
Other: Exercise
One type of exercise
A different type of exercise
Change in Dopamine release measured by RAC PET
Time frame: 4 months
The record gives a start of Nov 2014, a primary completion of Mar 2020 and a completion of Mar 2020. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pacific Parkinson's Research Centre